Liraglutide, semaglutide and tirzepatide: considerable evidence base

Weight reduction is an important therapeutic measure in diabetes prevention. Prediabetes is characterized by elevated fasting blood sugar and/or impaired glucose tolerance, but not yet manifest diabetes. In obese people, this stage represents a crucial time window for therapeutic interventions. Pharmacotherapy using incretin analogues in addition to conservative treatment can not only bring about a relevant weight reduction, but also contribute to a normalization of blood glucose levels, as a look at the study situation shows.